Washington, DC African-Americans are less likely than whites to receive critical stroke treatment primarily because they do not get to a hospital soon enough for time-sensitive treatment and because of preexisting medical conditions. For patients who are eligible for treatment, no racial disparity was found.
Those are the findings of a new Georgetown University Medical Center study involving the review of almost 1,000 patient records from all seven acute care hospitals in Washington, DC. The new study will be published in the June 30th issue of American Stroke Association's Stroke.
"Our study probably can be generalized to other urban communities in the US," says Chelsea Kidwell, MD, director of the Georgetown University Stroke Center. "The good news is that the results of the study provide important information on how to improve stroke treatment care in African-Americans in the future," she says.
The researchers looked at whether patients received the best drug possible to treat the most common type of stroke, called ischemic stroke. This type of stroke is caused by a blood clot that blocks blood flow in the brain. The drug tPA, or tissue plasminogen activator, is designed to break up the clot, which can reduce the effects of a stroke and reduce permanent disability. tPA is administered intravenously at a hospital and must be given within a few hours after the patient's initial symptoms. Previous studies, however, have suggested that blacks are less likely than whites to receive tPA. Researchers set out to determine if the disparity existed in the District of Columbia and if so, what the reasons might be.
For the study, Kidwell and her colleagues reviewed 973 records from patients hospitalized with ischemic stroke at all seven Washington, DC acute care hospitals. Of the patients, 80 percent were black, and 20 percent were non-Hispanic white.
"In Washington, a predominantly black urban population, we
'/>"/>
| Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center Source:Eurekalert |